<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">15828</article-id><article-id pub-id-type="doi">10.7554/eLife.15828</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-54105"><name><surname>Joseph</surname><given-names>James D</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-54106"><name><surname>Darimont</surname><given-names>Beatrice</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-54107"><name><surname>Zhou</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-54108"><name><surname>Arrazate</surname><given-names>Alfonso</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-54113"><name><surname>Young</surname><given-names>Amy</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-61196"><name><surname>Ingalla</surname><given-names>Ellen</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-54109"><name><surname>Walter</surname><given-names>Kimberly</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" id="author-54151"><name><surname>Blake</surname><given-names>Robert A</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf9"/></contrib><contrib contrib-type="author" id="author-54111"><name><surname>Nonomiya</surname><given-names>Jim</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf10"/></contrib><contrib contrib-type="author" id="author-54112"><name><surname>Guan</surname><given-names>Zhengyu</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf11"/></contrib><contrib contrib-type="author" id="author-54114"><name><surname>Kategaya</surname><given-names>Lorna</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf12"/></contrib><contrib contrib-type="author" id="author-54115"><name><surname>Govek</surname><given-names>Steven P</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf13"/></contrib><contrib contrib-type="author" id="author-54116"><name><surname>Lai</surname><given-names>Andiliy G</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf14"/></contrib><contrib contrib-type="author" id="author-54117"><name><surname>Kahraman</surname><given-names>Mehmet</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf15"/></contrib><contrib contrib-type="author" id="author-54118"><name><surname>Brigham</surname><given-names>Dan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf16"/></contrib><contrib contrib-type="author" id="author-54119"><name><surname>Sensintaffar</surname><given-names>John</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf17"/></contrib><contrib contrib-type="author" id="author-54120"><name><surname>Lu</surname><given-names>Nhin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf18"/></contrib><contrib contrib-type="author" id="author-54121"><name><surname>Shao</surname><given-names>Gang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf19"/></contrib><contrib contrib-type="author" id="author-54122"><name><surname>Qian</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf20"/></contrib><contrib contrib-type="author" id="author-54123"><name><surname>Grillot</surname><given-names>Kate</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf21"/></contrib><contrib contrib-type="author" id="author-54124"><name><surname>Moon</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf22"/></contrib><contrib contrib-type="author" id="author-54125"><name><surname>Prudente</surname><given-names>Rene</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf23"/></contrib><contrib contrib-type="author" id="author-54126"><name><surname>Bischoff</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf24"/></contrib><contrib contrib-type="author" id="author-54127"><name><surname>Lee</surname><given-names>Kyoung-Jin</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf25"/></contrib><contrib contrib-type="author" id="author-54128"><name><surname>Bonnefous</surname><given-names>Celine</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf26"/></contrib><contrib contrib-type="author" id="author-54129"><name><surname>Douglas</surname><given-names>Karensa L</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf27"/></contrib><contrib contrib-type="author" id="author-54130"><name><surname>Julien</surname><given-names>Jackaline D</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf28"/></contrib><contrib contrib-type="author" id="author-54131"><name><surname>Nagasawa</surname><given-names>Johnny Y</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf29"/></contrib><contrib contrib-type="author" id="author-54132"><name><surname>Aparicio</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf30"/></contrib><contrib contrib-type="author" id="author-54133"><name><surname>Kaufman</surname><given-names>Josh</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf31"/></contrib><contrib contrib-type="author" id="author-54134"><name><surname>Haley</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf32"/></contrib><contrib contrib-type="author" id="author-61197"><name><surname>Giltnane</surname><given-names>Jennifer M</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-54135"><name><surname>Wertz</surname><given-names>Ingrid E</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf33"/></contrib><contrib contrib-type="author" id="author-54136"><name><surname>Lackner</surname><given-names>Mark R</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf34"/></contrib><contrib contrib-type="author" id="author-54137"><name><surname>Nannini</surname><given-names>Michelle A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf35"/></contrib><contrib contrib-type="author" id="author-54138"><name><surname>Sampath</surname><given-names>Deepak</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf36"/></contrib><contrib contrib-type="author" id="author-54139"><name><surname>Schwarz</surname><given-names>Luis</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-54140"><name><surname>Manning</surname><given-names>Henry Charles</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-54141"><name><surname>Tantawy</surname><given-names>Mohammed Noor</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-14381"><name><surname>Arteaga</surname><given-names>Carlos L</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-54142"><name><surname>Heyman</surname><given-names>Richard A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf37"/></contrib><contrib contrib-type="author" id="author-54143"><name><surname>Rix</surname><given-names>Peter J</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf38"/></contrib><contrib contrib-type="author" id="author-54144"><name><surname>Friedman</surname><given-names>Lori</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf39"/></contrib><contrib contrib-type="author" id="author-54145"><name><surname>Smith</surname><given-names>Nicholas D</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf40"/></contrib><contrib contrib-type="author" corresp="yes" id="author-52842"><name><surname>Metcalfe</surname><given-names>Ciara</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7233-661X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf41"/></contrib><contrib contrib-type="author" corresp="yes" id="author-54149"><name><surname>Hager</surname><given-names>Jeffrey H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="fn" rid="conf42"/></contrib><aff id="aff1"><institution content-type="dept">Department of Biology</institution>, <institution>Seragon Pharmaceuticals</institution>, <addr-line><named-content content-type="city">San Diego</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Translational Oncology</institution>, <institution>Genentech</institution>, <addr-line><named-content content-type="city">South San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Department of Oncology Biomarker Development</institution>, <institution>Genentech</institution>, <addr-line><named-content content-type="city">South San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Department of Biochemical and Cellular Pharmacology</institution>, <institution>Genentech</institution>, <addr-line><named-content content-type="city">South San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Department of Discovery Oncology</institution>, <institution>Genentech</institution>, <addr-line><named-content content-type="city">South San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">Department of Chemistry</institution>, <institution>Seragon Pharmaceuticals</institution>, <addr-line><named-content content-type="city">San Diego</named-content></addr-line>, <country>United States</country></aff><aff id="aff7"><institution content-type="dept">Department of Drug Safety and Disposition</institution>, <institution>Seragon Pharmaceuticals</institution>, <addr-line><named-content content-type="city">San Diego</named-content></addr-line>, <country>United States</country></aff><aff id="aff8"><institution content-type="dept">Department of Molecular Biology</institution>, <institution>Genentech</institution>, <addr-line><named-content content-type="city">South San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff9"><institution content-type="dept">Department of Pathology</institution>, <institution>Genentech</institution>, <addr-line><named-content content-type="city">South San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff10"><institution content-type="dept">Department of Medicine and Breast Cancer Program</institution>, <institution>Vanderbilt-Ingram Cancer Center</institution>, <addr-line><named-content content-type="city">Nashville</named-content></addr-line>, <country>United States</country></aff><aff id="aff11"><institution content-type="dept">Vanderbilt University Institute of Imaging Sciences</institution>, <institution>Vanderbilt University</institution>, <addr-line><named-content content-type="city">Nashville</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-3664"><name><surname>Katzenellenbogen</surname><given-names>John A</given-names></name><role>Reviewing editor</role><aff><institution>University of Illinois at Urbana-Champaign</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>metcalfe.ciara@gene.com</email> (CM);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>jeff.hager@icloud.com</email> (JH);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>13</day><month>07</month><year>2016</year></pub-date><volume>5</volume><elocation-id>e15828</elocation-id><supplementary-material><ext-link xlink:href="elife-15828-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>07</day><month>03</month><year>2016</year></date><date date-type="accepted"><day>09</day><month>07</month><year>2016</year></date></history><permissions><copyright-statement>© 2016, Joseph et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Joseph et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>ER-targeted therapeutics provide valuable treatment options for patients with ER+ breast cancer, however, current relapse and mortality rates emphasize the need for improved therapeutic strategies. The recent discovery of prevalent ERα mutations in relapsed tumors underscores a sustained reliance of advanced tumors on ERα signaling, and provides a strong rationale for continued targeting of ERα. Here we describe GDC-0810, a novel, non-steroidal, orally bioavailable selective ER downregulator (SERD), which was identified by prospectively optimizing ERα degradation, antagonism and pharmacokinetic properties. GDC-0810 induces a distinct ERα conformation, relative to that induced by currently approved therapeutics, suggesting a unique mechanism of action. GDC-0810 has robust <italic>in vitro</italic> and <italic>in vivo</italic> activity against a variety of human breast cancer cell lines and patient derived xenografts, including a tamoxifen-resistant model and those that harbor ERα mutations. GDC-0810 is currently being evaluated in Phase II clinical studies in women with ER+ breast cancer.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>James D Joseph, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf3"><p>Beatrice Darimont, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf4"><p>Wei Zhou, Employed by Genentech and own shares.</p></fn><fn fn-type="conflict" id="conf5"><p>Alfonso Arrazate, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf6"><p>Amy Young, Employed by Genentech and own shares.</p></fn><fn fn-type="conflict" id="conf7"><p>Ellen Ingalla, Employed by Genentech and own shares.</p></fn><fn fn-type="conflict" id="conf8"><p>Kimberly Walter, Employed by Genentech and own shares.</p></fn><fn fn-type="conflict" id="conf9"><p>Robert A Blake, Employed by Genentech and own shares.</p></fn><fn fn-type="conflict" id="conf10"><p>Jim Nonomiya, Employed by Genentech and own shares.</p></fn><fn fn-type="conflict" id="conf11"><p>Zhengyu Guan, Employed by Genentech and own shares.</p></fn><fn fn-type="conflict" id="conf12"><p>Lorna Kategaya, Employed by Genentech and own shares.</p></fn><fn fn-type="conflict" id="conf13"><p>Steven P Govek, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf14"><p>Andiliy G Lai, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf15"><p>Mehmet Kahraman, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf16"><p>Dan Brigham, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf17"><p>John Sensintaffar, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf18"><p>Nhin Lu, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf19"><p>Gang Shao, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf20"><p>Jing Qian, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf21"><p>Kate Grillot, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf22"><p>Michael Moon, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf23"><p>Rene Prudente, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf24"><p>Eric Bischoff, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf25"><p>Kyoung-Jin Lee, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf26"><p>Celine Bonnefous, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf27"><p>Karensa L Douglas, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf28"><p>Jackaline D Julien, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf29"><p>Johnny Y Nagasawa, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf30"><p>Anna Aparicio, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf31"><p>Josh Kaufman, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf32"><p>Benjamin Haley, Employed by Genentech and own shares.</p></fn><fn fn-type="conflict" id="conf33"><p>Ingrid E Wertz, Employed by Genentech and own shares.</p></fn><fn fn-type="conflict" id="conf34"><p>Mark R Lackner, Employed by Genentech and own shares.</p></fn><fn fn-type="conflict" id="conf35"><p>Michelle A Nannini, Employed by Genentech and own shares.</p></fn><fn fn-type="conflict" id="conf36"><p>Deepak Sampath, Employed by Genentech and own shares.</p></fn><fn fn-type="conflict" id="conf37"><p>Richard A Heyman, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf38"><p>Peter J Rix, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf39"><p>Lori Friedman, Employed by Genentech and own shares.</p></fn><fn fn-type="conflict" id="conf40"><p>Nicholas D Smith, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf41"><p>Ciara Metcalfe, Employed by Genentech and own shares.</p></fn><fn fn-type="conflict" id="conf42"><p>Jeffrey H Hager, Shareholder of Seragon.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Animal studies were conducted in accordance with the Guide for the Care and Use of Laboratory Animals, National Academy Press (2006), conforming to California State legal and ethical practices and approved by the Institutional Animal Care and Use Committee (IACUC, Seragon and/or Genentech).</p></fn></fn-group></sec></back></article>